)
ABOUT
EFFective founder Emilee Friedman Fechter is a Nashville-based certified medical writer. She has a BS in Biology from Augusta University and an MS in Biology from Georgia College & State University.
After earning her MS degree in Biology, Emilee worked at the Vanderbilt Vaccine Center's Georgiev Lab. As a research assistant, she contributed to antibody discovery and characterization for the development of vaccines against numerous viruses, including HIV, HCV, and SARS-CoV-2. In this role, she authored and contributed to numerous grant applications, IRB applications, and publications.
Emilee next served as the Regulatory Coordinator for a retina surgery center's clinical research program, supporting more than 50 clinical trials and ensuring regulatory compliance. In this position, she earned her Advanced ICH GCP Certification (AGCPC), demonstrating dedication to ethical conduct of research at various stages. Upon completion of her role as the Regulatory Coordinator, Emilee returned to Vanderbilt, as a Research Project Coordinator at the Vanderbilt Institute for Clinical and Translational Research (VICTR). For the next several years, Emilee supported various clinical trials through VICTR's Drug Repurposing project management team. A noteworthy contribution was to the NHLBI-funded ACTIV-4 Host Tissue trial, which assesses the role of the Renin-Angiotensin-Aldosterone System (RAAS) during COVID-19 infection and published on its outcome framework in Chest, a pulmonary and critical care journal.
Emilee next served as the Regulatory Coordinator for a retina surgery center's clinical research program, supporting more than 50 clinical trials and ensuring regulatory compliance. In this position, she earned her Advanced ICH GCP Certification (AGCPC), demonstrating dedication to ethical conduct of research at various stages. Upon completion of her role as the Regulatory Coordinator, Emilee returned to Vanderbilt, as a Research Project Coordinator at the Vanderbilt Institute for Clinical and Translational Research (VICTR). For the next several years, Emilee supported various clinical trials through VICTR's Drug Repurposing project management team. A noteworthy contribution was to the NHLBI-funded ACTIV-4 Host Tissue trial, which assesses the role of the Renin-Angiotensin-Aldosterone System (RAAS) during COVID-19 infection and published on its outcome framework in Chest, a pulmonary and critical care journal.
At VICTR, Emilee facilitated protocol development for an investigator-initiated oncology pilot trial repurposing a thromboxane A2 receptor (TXA2R) antagonist for prevention of metastatic recurrence. She also provided operational support for the ClearMEMory trial, which seeks to repurpose FDA-approved Memantine in systemic lupus erythematosus.
In June 2023, Emilee successfully passed the American Medical Writers Association (AMWA)'s Medical Writing Certification (MWC) exam, joining a group of fewer than 200* MWCs nationwide. *As of February 2025
In June 2023, Emilee successfully passed the American Medical Writers Association (AMWA)'s Medical Writing Certification (MWC) exam, joining a group of fewer than 200* MWCs nationwide. *As of February 2025